Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE BayeSize applies the concept of effect size ...
Conflicting findings are often reported in microbiome association studies, which could be due to insufficient sample sizes and numerous confounders. A new study, utilizing two large-scale human ...
A new method could be used to estimate the prevalence of disease in free-ranging wildlife and help determine how many samples are needed to detect a disease. A new method could be used to estimate the ...
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the ...
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results